Advertisements

Phase 2a Safety and Efficacy Data Support Further Development of Oral CC-220 in Patients with Lupus

Phase 2a Safety and Efficacy Data Support Further Development of Oral CC-220 in Patients with Lupus.....»»

Category: press-releasesSource: businesswireindiaJun 14th, 2017

Phase III Efficacy and Safety Data for Oral Ozanimod in Relapsing Multiple Sclerosis to Be Presented at MSParis2017 – 7th Joint ECTRIMS – ACTRIMS Meeting

Phase III Efficacy and Safety Data for Oral Ozanimod in Relapsing Multiple Sclerosis to Be Presented at MSParis2017 – 7th Joint ECTRIMS – ACTRIMS Meeting.....»»

Category: press-releasesSource: businesswireindiaOct 20th, 2017

Efficacy and Safety Results from Second Phase III Trial (RADIANCE™ Part B) of Oral Ozanimod Versus an Active Comparator in Relapsing Multiple Sclerosis Presented at MSParis2017 – 7th Joint ECTRIMS – ACTRIMS Meeting

Efficacy and Safety Results from Second Phase III Trial (RADIANCE™ Part B) of Oral Ozanimod Versus an Active Comparator in Relapsing Multiple Sclerosis Presented at MSParis2017 – 7th Joint ECTRIMS – ACTRIMS Meeting.....»»

Category: press-releasesSource: businesswireindiaOct 28th, 2017

Efficacy and Safety Results from First Phase III Trial of Oral Ozanimod (SUNBEAM™) Versus an Active Comparator in Relapsing Multiple Sclerosis Presented at MSParis2017 – 7th Joint ECTRIMS – ACTRIMS Meeting

Efficacy and Safety Results from First Phase III Trial of Oral Ozanimod (SUNBEAM™) Versus an Active Comparator in Relapsing Multiple Sclerosis Presented at MSParis2017 – 7th Joint ECTRIMS – ACTRIMS Meeting.....»»

Category: press-releasesSource: businesswireindiaOct 28th, 2017

Updated Data from Phase 1 Trial of Oral IDHIFA® (enasidenib) Demonstrate Complete Responses and Duration of Response in Patients with Relapsed or Refractory AML and an IDH2 Mutation

Updated Data from Phase 1 Trial of Oral IDHIFA® (enasidenib) Demonstrate Complete Responses and Duration of Response in Patients with Relapsed or Refractory AML and an IDH2 Mutation.....»»

Category: press-releasesSource: businesswireindiaJun 7th, 2017

Uber launches #39;Movement#39; in India to support data-driven urban planning

Uber launches #39;Movement#39; in India to support data-driven urban planning.....»»

Category: topSource: moneycontrolApr 12th, 2018

Glenmark Pharmaceuticals Announces Top-line Results From a Phase 3 Safety Study Evaluating Ryaltris in Patients With Perennial Allergic Rhinitis

Glenmark Pharmaceuticals Announces Top-line Results From a Phase 3 Safety Study Evaluating Ryaltris in Patients With Perennial Allergic Rhinitis.....»»

Category: press-releasesSource: prnewswireDec 14th, 2017

Efficacy and safety maintained in patients who switched from Humira® to biosimilar Cyltezo®

Efficacy and safety maintained in patients who switched from Humira® to biosimilar Cyltezo®.....»»

Category: press-releasesSource: businesswireindiaNov 7th, 2017

Altemia™ Achieves Successful Clinical Results in Pediatric Patients with Sickle Cell Disease (SCD)

Altemia™ Achieves Successful Clinical Results in Pediatric Patients with Sickle Cell Disease (SCD).....»»

Category: press-releasesSource: businesswireindiaNov 2nd, 2017

Takeda to Feature ALUNBRIG™ (brigatinib) Data from Pivotal Phase 2 ALTA Trialat 18th World Conference on Lung Cancer

Takeda to Feature ALUNBRIG™ (brigatinib) Data from Pivotal Phase 2 ALTA Trialat 18th World Conference on Lung Cancer.....»»

Category: press-releasesSource: businesswireindiaSep 28th, 2017

Publication of Clinical Data Demonstrating Low Immunogenicity and Excellent Efficacy of Nuwiq® in Previously Untreated Patients

Publication of Clinical Data Demonstrating Low Immunogenicity and Excellent Efficacy of Nuwiq® in Previously Untreated Patients.....»»

Category: press-releasesSource: businesswireindiaAug 23rd, 2017

Glenmark’s dermatitis molecule displays positive results in phase-2a trial

Glenmark’s dermatitis molecule displays positive results in phase-2a trial.....»»

Category: featuresSource: livemintAug 1st, 2017

Takeda Presents Data from Phase 1/2 Studies for NINLARO™ (ixazomib) in Newly Diagnosed Multiple Myeloma Patients and in the Maintenance Setting

Takeda Presents Data from Phase 1/2 Studies for NINLARO™ (ixazomib) in Newly Diagnosed Multiple Myeloma Patients and in the Maintenance Setting.....»»

Category: press-releasesSource: businesswireindiaJun 24th, 2017

Results of Phase III RELEVANCE Study Comparing REVLIMID plus Rituximab (R2) Versus Rituximab Plus Chemotherapy in Patients with Previously Untreated Follicular Lymphoma to be Presented at ASCO 2018

Results of Phase III RELEVANCE Study Comparing REVLIMID plus Rituximab (R2) Versus Rituximab Plus Chemotherapy in Patients with Previously Untreated Follicular Lymphoma to be Presented at ASCO 2018.....»»

Category: press-releasesSource: businesswireindiaJun 4th, 2018

IT Ministry asks NPCI to check compliance of WhatsApp payments, data safety: Sources - Economic Times

IT Ministry asks NPCI to check compliance of WhatsApp payments, data safety: Sources - Economic Times.....»»

Category: topSource: googlenewsJun 2nd, 2018

IT Ministry asks NPCI to check compliance of WhatsApp payments, data safety: Sources - Daily News & Analysis

IT Ministry asks NPCI to check compliance of WhatsApp payments, data safety: Sources - Daily News & Analysis.....»»

Category: topSource: googlenewsJun 2nd, 2018

India resists lobbying by U.S. payment firms to ease local data storage rules

India resists lobbying by U.S. payment firms to ease local data storage rules.....»»

Category: topSource: the-hinduMay 30th, 2018

Octapharma present new data on the benefits of Nuwiq® in patients with haemophilia A at the World Federation of Hemophilia 2018 World Congress

Octapharma present new data on the benefits of Nuwiq® in patients with haemophilia A at the World Federation of Hemophilia 2018 World Congress.....»»

Category: press-releasesSource: businesswireindiaMay 28th, 2018

Equity indices rise as oil prices fall

Equity indices rise as oil prices fall.....»»

Category: marketsSource: sifyMay 25th, 2018

SIDBI to provide financial support to Village Level Entrepreneurs

SIDBI to provide financial support to Village Level Entrepreneurs.....»»

Category: topSource: newsonairMay 24th, 2018

See strong support for Nifty around 10,418 levels

See strong support for Nifty around 10,418 levels.....»»

Category: topSource: moneycontrolMay 24th, 2018